Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Obesity

Ozempic For Pets: New Drug Being Tested For Animal Obesity - Here's What We Know

Scientists test OKV-119, a six-month implant dubbed 'Ozempup', as a new Ozempic for pets to fight obesity in cats and dogs amid rising pet health risks.

International Business Times UK

Manufacturers given 18 months to cut sugar and salt in baby food products

New labelling guidelines will also help parents make informed choices about what they feed their children.

Evening Standard

Deadline set for manufacturers to cut sugar and salt in baby food

New data shows that more than two thirds of children aged 18 months to three years are eating too much sugar

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Obesity has a serious impact on health – it shortened my mum’s life

Letter: Blaming the patriarchy, fatphobia or big pharma doesn’t reduce the risks of being overweight, says Frances Knight

The Guardian - UK

Viking's 42% Plunge Splits Experts—A '$129 Strong Buy' Or 'Clearly Inferior' Drug?

Viking Therapeutics Inc. (NASDAQ:VKTX) saw its stock collapse by over 42% on Tuesday after data from its Phase 2 obesity pill trial disappointed investors, sparking a fierce debate between Wall Street bulls and critical biotech experts.

Benzinga

Palantir, AMD, Oracle, Viking And Nvidia: Why These 5 Stocks Are On Investors' Radars Today

U.S. stock indices closed mixed on Tuesday, with the Dow Jones Industrial Average edging up 0.02% to 44,922.27. The SP 500 slipped 0.6% to 6,411.37, while the Nasdaq saw a steeper drop, tumbling nearly 1.5% to 21,314.95.These are the top stocks that gained the attention of retail traders and investors…

Benzinga

Market Bloodbath: Viking Therapeutics Stock Tanks After Obesity Pill Side Effects Trigger Mass Dropouts

Viking Therapeutics shares plunged 40% after trial data for its obesity pill, VK2735, revealed high dropout rates due to side effects, raising doubts about its competitiveness against rivals Eli Lilly and Novo Nordisk.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill.

Benzinga

New Obesity Drugs May See Premium Pricing Undermined By Underwhelming Data

Eli Lilly and Co. (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO) are expected to launch new obesity-treatment pills in the U.S. next year at prices comparable to their existing injectable drugs, signaling a break from the industry trend of charging more for new therapies.

Benzinga

Puppy fat implants: are our pets next in line for weight-loss drugs?

A biotech firm has announced trials for a dog implant that mimics the drugs taken by humans to help tackle obesity

The Guardian - UK

Novo Nordisk's Lead Fades, Eli Lilly Holds Course For Outsized Gains, Says Analyst

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom.

Benzinga

Ultra-processed foods might not be the real villain in our diets – here’s what our research found

Ultra-processed foods (UPFs) have become public enemy number one in nutrition debates. From dementia to obesity and an epidemic of “food addiction”, these factory-made products, including crisps, ready meals, fizzy drinks and packaged snacks, are blamed for a wide range of modern health problems. Some experts argue that they’re “specifically…

The Conversation

Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs

Eli Lilly and Co (NYSE:LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other cardiometabolic diseases.

Benzinga

Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India

Eli Lilly and Co. (NYSE:LLY) will sharply increase the list price of its weight-loss and type 2 diabetes drug Mounjaro (tirzepatide) in the United Kingdom, while expanding its market presence in India with a new injector pen.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Wolverhampton cemetery’s extra fee for wider graves criticised as ‘fat tax’

Council says measure at Danescourt cemetery in Tettenhall is in response to increase in obesity levels in city

Benzinga

Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens

Vacations are on hold, dinners out skipped, and doses stretched — all so patients can keep taking weight-loss drugs like Wegovy and Zepbound as insurers pull back coverage in 2025.

Benzinga

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and…

The Independent UK

The targeted programme found to improve IVF outcomes

Women who took part in a weight loss programme had a 21 per cent higher chance of becoming pregnant – whether naturally or through IVF

Get all your
news in one place.

100's of premium titles.
One news app.

Fortune

Trump wants Medicare to pay for your Ozempic treatment. Taxpayers may foot the bill for billions in fraud

As lawyers who represent whistleblowers under the False Claims Act, we expect a new era of fraud cases tied to GLP-1 drugs, including Wegovy, Ozempic, and Mounjaro.

Evening Standard

Government partners with Mounjaro maker to tackle obesity

The £85 million programme will looks at ways for patients to access services more easily.

The Conversation

Weight loss support before IVF could boost pregnancy chances – and reduce the need for treatment

Around one in five women of childbearing age are living with [obesity], defined by the World Health Organization as having a body mass index (BMI) over 30 kg/m². Compared with women in the healthy BMI range (18.5–24.9 kg/m²), those living with obesity are three times more likely to experience fertility…

The Conversation

Ozempic and other weight-loss drugs linked to rare but serious eye conditions

Drugs such as Ozempic, Wegovy and Mounjaro (known as semaglutide and tirzepatide) have changed the way clinicians manage diabetes and obesity around the world.

Benzinga

Novo Nordisk Stock Climbs Over 4% In Friday Pre-Market: What's Going On?

Shares of Novo Nordisk A/S (NYSE:NVO) climbed 4.29% during Friday’s pre-market trading session, after rival Eli Lilly (NYSE:LLY)’s Phase 3 ATTAIN-1 trial for obesity drug, orforglipron, trailed the Danish drug giant’s semaglutide on Thursday.

Euronews

Portugal tightens rules on weight loss drug prescriptions to prevent misuse

Doctors from only four medical specialties will be able to write prescriptions for injectable drugs that are used to treat type 2 diabetes and obesity but are also popular for weight loss.

Barchart

This Blue-Chip Stock Is Cooking Up a Major Growth Catalyst

Eli Lilly is poised for a major boost as new data shows its diabetes drug Mounjaro offers heart health benefits, potentially making it the top choice for patients with Type 2 diabetes.

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

627 stories

CMS

533 stories

Advanced Micro Devices

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Dow Jones Industrial Average

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.